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James A. Russell,1 William Irish,2 Alexander Balogh,1 M. Ahsan Chaudhry,1
Mary Lynn Savoie,1 A. Robert Turner,3 Loree Larratt,3 Jan Storek,1 Nizar J. Bahlis,1
Christopher B. Brown,1 Diana Quinlan,1 Michelle Geddes,1 Nancy Zacarias,1 Andrew Daly,1
Peter Duggan,1 Douglas A. Stewart1A combination of fludarabine (Flu) and daily i.v. busulfan (Bu) is well tolerated and effective in patients under-
going allogeneic hematopoietic stem cell transplantation (HSCT) for acutemyelogenous leukemia (AML). The
addition of rabbit antithymocyte globulin (ATG) may reduce morbidity and mortality from graft-versus-host
disease (GVHD), but lead to increased relapse. To compensate for this effect, we added 400 cGy of total body
irradiation (TBI) to the Flu/Bu regimen in 89 patients, and compared outcomes with those achieved in 90 pa-
tients who received the drug combination alone. Although nonrelapse mortality (NRM) at 3 years did not dif-
fer between the groups, the inclusion of TBI significantly reduced relapse (hazard ratio [HR] 5 0.29; 95%
confidence interval [CI] 5 0.15-0.54; P 5 .0001). Consequently, both overall survival (OS; HR 5 0.50; 95%
CI5 0.3-0.84; P5 .009) and disease-free survival (DFS; HR5 0.43; 95% CI5 0.26-0.72; P5 .001) were im-
proved with the inclusion of TBI. This study confirms the importance of regimen intensity in allogeneic HSCT
for AML. The combination of daily i.v. Bu, Flu, 400 cGy TBI, and ATG provides a well-tolerated regimen with
antileukemic activity in AML comparable to that of other, conventional myeloablative (MA) regimens.
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There is evidence that the intensity of the pretrans-
plantation conditioning regimen is partly responsible
for the ability of allogeneic hematopoietic stem cell
transplantation (HSCT) to cure acute myelogenous
leukemia (AML). Attempts to increase the intensity of
conventional myeloablative regimens have sometimes
resulted in less relapse but no better survival, because1Departments of Medicine and Oncology, Foothills Hos-
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6/j.bbmt.2009.11.017of higher nonrelapse mortality (NRM) [1,2]. Reduced-
intensity conditioning (RIC) regimens are associated
with higher relapse rates then fully myeloablative (MA)
protocols [3]. A combination of fludarabine (Flu) and
daily i.v. busulfan (Bu) is effective in AML and relatively
well tolerated [4]. The addition of rabbit antithymocyte
globulin (ATG) to this regimen reduces morbidity and
mortality from graft-versus-host disease (GVHD), but
may lead to more relapse [5,6]. To address this issue,
we added a low dose of total body irradiation (TBI) to
a Flu/Bu combination before HSCT for patients with
AML [7]. We compared outcomes in patients receiving
additional TBI and those receiving Flu/Bu alone.PATIENTS AND METHODS
Patients
This study is a retrospective analysis of outcomes
of 179 consecutive adults treated with a first MA509
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noses and other details of the 2 groups are presented in
Table 1. Patients in second complete remission (CR2)
are included in the low-risk (LR) group because out-
comes, including NRM, are similar to those for pa-
tients in CR1 with this regimen.
When we first used the Flu/Bu regimen, TBI was
added only for patients with extramedullary disease.
As it became apparent that additional TBI was well
tolerated by patients with acute lymphoblastic leuke-
mia (ALL), TBI was added to the regimen for high-
risk patients, and then finally for every patient. Thus,
the cohort receiving TBI has a somewhat shorter
follow-up than the non-TBI group, but management
was similar in other respects.
To determine whether improved outcomes in TBI
recipients could be attributed to changes occurring
with time in, for example, supportive care, we analyzed
outcomes in patients treated within 1 year of May 15,Table 1. Patient and Transplant Characteristics
No TBI TBI
Number 90 89
Patient age, years, median
(range)
42 (16-65) 46 (18-66)
Male 45 (50%) 47 (53%)
Low-risk disease 56 (62%) 67 (75%)
Secondary leukemia/previous
MDS
0* 9 (13%)
CR1 45 (80%)† 48 (72%)
CR2 11 (20%) 19 (28%)
High-risk disease 34 (38%) 22 (25%)
Secondary leukemia/previous
MDS
19 (56%)† 10 (38%)
Relapse 8 (24%) 8 (36%)
Refractory 15 (44%) 12 (55%)
Untreated 11 (32%)‡ 1 (5%)
CR3 1 (5%)
Cytogenetic risk group§
1 8 (10%)¶ 9 (11%)k
2 57 (72%) 53 (65%)
3 14 (18%) 20 (24%)
Alternate donor 40 (44%) 49 (55%)
Mismatched related donor 10 (11%) 2 (2%)
Matched unrelated donor 23 (26%) 29 (33%)
Mismatched unrelated donor 7 (8%) 18 (20%)
CMV antibody–positive
recipient or donor
68 (76%) 60 (67%)
Female to male SCT 19 (21%) 18 (20%)
Blood as stem cell source 66 (73%)** 82 (92%)
CD 34+ cell dose,  10e6/kg,
median (range)
4.3 (0.64-23.87)* 5.9 (0.75-17.69)
Follow-up of survivors, months,
median (range)
80 (45-101)* 31 (12-83)
CR1 indicates first clinical remission; CR2, second clinical remission,
MDS, myelodysplastic syndrome; SCT, stem cell transplantation.
+Data are reported as n (%) unless indicated otherwise.
*P <.0001.
†Percentage of low-risk/high-risk disease.
‡P 5 .002.
§1, t(8:21), inv 16, t(15:17); 3, complex karyotype, abnormalities of 5 and
7; 2, all others.
¶O 79 results.
kO 82 results.
**P 5 .001.2003. Three patients received TBI before this date,
and 4 patients were treated without TBI afterward.
Over the 2-year period, 28 patients received TBI and
23 did not receive TBI. When significant prognostic
factors for disease-free survival (DFS) and overall sur-
vival (OS) were considered, the 2 groups had a similar
median age (46 years vs 47 years), as well as similar pro-
portions of low-risk patients (61% vs 61%) and blood
cell recipients (89% vs 87%). There was a trend toward
more with high-risk cyogenetics in the TBI recipients
(29% vs 9%; P 5 .09).
More patients in the non-TBI group received bone
marrow (BM), because this was the only product avail-
able from many unrelated donors in the earlier part of
the study.
Our Institutional Review Board approved the
protocol, outcome analysis, and informed consent
form, which each participant signed.Treatment
The preparative chemotherapy comprised Flu 50
mg/m2 on days26 to22 and i.v. Bu (Busulfex; Otsuka
Pharma, Rockville,MD) 3.2mg/kg daily on days25 to
22 inclusive. Eighty-nine patients received additional
TBI, 200 cGy  2 on day 21 or 0. Busulfan pharma-
cokinetics weremonitored in some patients, but results
were not used to make dose adjustments.
Supportive carewas similar for all patients.Nopro-
tective isolation was used [8]. Single donor platelets
were given to maintain counts at .10  109/L and
red cells were given to maintain hemoglobin level at
.80 g/L. Growth factors were not given routinely.
All patients received twice-weekly trimethoprim/sulfa-
methoxazole as prophylaxis for Pneumocystis carinii.
Antibacterial prophylaxis was ciprofloxacin 500 mg
twice daily until 2003, after which time no antibacterial
antibiotics were given routinely. All blood products
used were from cytomegalovirus (CMV)-seronegative
donors. A policy of surveillance for pp65 antigen and
preemptive therapy with ganciclovir was implemented
when the donor and/or recipient were CMV antibody–
positive. Routine monitoring for Epstein-Barr virus
(EBV) viral load was not done. The acute GVHD
(aGVHD) prophylaxis protocol included cyclosporine
A (CsA) orally or i.v. twice daily to maintain a blood
level between 150 and 400 mmol/L. Methotrexate
(MTX) 15 mg/m2 i.v. was given on day 1 and 10 mg/
m2 was given on days 3, 6, and 11. Folinic acid 5 mg
i.v. or orally was started 24 hours after each MTX
dose and continued every 6 hours until 12 hours before
the next dose [9]. In addition, all patients were given
rabbit ATG (Thymoglobulin; Genzyme, Cambridge,
MA) 4.5 mg/kg i.v. in divided doses over 3 days. Each
dose was given as a continuous infusion over 4-8 hours.
Tominimize reactions, the first dosewas reduced to 0.5
mg/kg, the next 2 doses were 2 mg/kg, and the final
Biol Blood Marrow Transplant 16:509-514, 2010 511TBI with Flu/Bu/Thymoglobulin for AMLinfusion was administered on the day of transplanta-
tion. Premedication included methylprednisolone 40
mg i.v. every 12 hours for 6 doses and benadryl 50 mg
i.v. before each dose of ATG.
If aGVHD did not occur, then CsA was tapered
over 4-8 weeks, with the intent to discontinue by 2-4
months posttransplantation.
Engraftment
Daily blood counts were monitored until dis-
charge; BM aspirations were performed at 3 months
for surviving patients and thereafter as clinically indi-
cated. Granulocyte engraftment was defined as a count
of .0.5  109/L for 3 consecutive days. The platelet
count needed to be above 20  109/L without transfu-
sion for 7 days for documentation of engraftment.
Graft-versus-Host Disease
aGVHDwas graded according to standard criteria
[10]. Grading was performed by physicians at the onset
of treatment and throughout treatment, with later con-
firmation and recording by data managers. aGVHD
was treated with prednisone or methylprednisolone
initially while continuing CsA. First-line therapy for
steroid-resistant aGVHD was ATG 2 mg/kg every
other day, for 2-4 doses, while CsA was withheld.
Chronic GVHD (cGVHD) was treated with predni-
sone with or without CsA, with introduction of other
agents if response was incomplete.
Statistical Analysis
Continuous data are presented as median and
range, and categorical data are given as counts and per-
centages. Survivorship function of time-to-event data
was estimated using the product-limit method and
compared using the log-rank test. For analysis of
time to NRM, patients were right-censored at time
of relapse, and for analysis of onset of cGVHD,
patients were right-censored at the time of death,
donor lymphocyte infusion (DLI), or second trans-
plantation. Clinical endpoints of relapse, NRM,
DFS, and OS were recorded at 3 years from HSCT.
Statistical analyses were performed with GraphPad
Prism (GraphPad, San Diego, CA).
Multivariate Cox hazards regression was used to
identify factors associated with rates of relapse,
NRM, relapse or death, mortality, aGVHD, and
cGVHD. TBI versus no TBI was included in all
models regardless of the statistical significance for out-
come. Hazard ratio (HR) and associated 95% confi-
dence interval (CI) were used as measures of strength
of association and precision, respectively. Cox hazards
regression was performed using SAS version 9.1 (SAS
Institute, Cary, NC). For all analyses, P values\.10
are reported as trends, and those\.05 are considered
statistically significant.RESULTS
Engraftment
Of the patients who did not receive TBI, one died
before day 17 without engraftment, and one under-
went retransplantation at day 190 for graft failure.
The remaining 88 evaluable patients engrafted granu-
locytes at median of 19 days (range, 11-113 days). Five
patients with granulocyte recovery failed to achieve
platelet engraftment, 4 because of relapse and 1
because of hemolytic uremic syndrome and death on
day 54. The remaining 83 patients demonstrated
platelet recovery between days 0 and 120 (median,
day 19).
One TBI recipient died without engraftment on
day 8. The remaining 88 evaluable patients engrafted
granulocytes at a median of 15 days (range, 10-50
days). Two patients with granulocyte recovery failed
to achieve platelet engraftment because of NRM, one
on day 29 and the other on day 54. The remaining
86 patients achieved platelet recovery between days 5
and 89 (median, day 19).Posttransplantation Lymphoproliferative
Disease
Eleven TBI recipients developed posttransplanta-
tion lymphoproliferative disease (PTLD), one after
treatment of GVHD with ATG. All responded to
withdrawal of immune suppression with or without
rituximab and, in one case, donor lymphocyte infu-
sion.Graft-versus-Host Disease
For patients not receiving and receiving TBI, the
incidence of aGVHD grade II-IV was 15% vs 23%,
that of aGVHD grade III-IV was 8% vs 9%, and
that of cGVHD was 62% vs 55%, respectively. None
of these differences are significant.
By multivariate Cox hazard regression analysis, the
only factors associated with aGVHD grade II-IV were
the use of an alternate donor (HR 5 2.92; 95% CI 5
1.30-6.52; P 5 .009) and positive donor and/or recip-
ient CMV status (HR 5 2.58; 95% CI 5 1.05-6.33;
P 5 .039). There was a trend toward an increased
risk of aGVHD in male recipients of female donors
(HR 5 2.08; 95% CI 5 0.94-4.60; P 5 .069), high-
risk disease status (HR for high risk vs low risk 5
1.93; 95% CI 5 0.94-3.95; P 5 .072), and stem cell
source (HR for blood cells vs BM 5 2.64; 95% CI 5
0.83-8.38; P 5 .099).
Factors associated with cGVHD were disease
status (HR for high-risk disease vs low-risk 5 2.13;
95% CI 5 1.31-3.47; P 5 .002) and cytogenetic
group (HR for group 3 vs group 2 5 0.41; 95% CI 5
0.19-0.874; P5 .021).
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Figure 1. Kaplan-Meier plots of OS (A) and DFS (B). Solid lines, TBI;
dashed lines, no TBI.
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Table 2 lists the causes of NRM. There was no
difference in NRM between patients who did and did
not receive TBI (adjusted HR 5 1.12; 95% CI 5
0.48-2.60; P 5 .796); NRM was 13% versus 9% in
low-risk patients and 27% and 31% in high-risk
patients. There was a trend toward more NRM in
male recipients of female donor HSCT (HR 5 2.09;
95% CI 5 0.88-4.96; P 5 .095).
Relapse
In low-risk patients, the incidence of relapse was
32% in those not receiving TBI and 16% in those re-
ceiving TBI (P5 .08). Corresponding figures for high-
risk patients were 79% and 33% (P 5 .003).
By multivariate Cox hazard regression analysis, the
only factors significantly associated with relapse were
disease status (HR for high-risk disease 5 3.45; 95%
CI 5 1.98-6.02; P\.0001), cytogenetic group 3 com-
pared with group 2 HR 5 3.27; 95% CI 5 1.70-6.26
(P 5 .0004), age (HR per 1-year increase 5 1.03;
95% CI 5 1.01-1.06; P 5 .015), and the use of TBI
(HR 5 0.29; 95% CI 5 0.15-0.54; P 5 .0001).
aGVHD or cGVHD had no influence on relapse.
DFS and OS
Figure 1 compares DFS and OS in the 2 risk
groups. In low-risk patients with and without TBI,
DFS was 59% versus 77% (P 5 .04) and OS was
64% versus 78% (P 5 not significant), respectively.
Corresponding figures for high-risk disease were
15% versus 46% (P 5 .02) for DFS and 26% versus
51% (P 5 .05) for OS. Both DFS and OS were influ-
enced by TBI, age, cytogenetic risk group, disease
status, and stem cell source (Table 3).Table 2. Causes of NRM
Death before Day
100
Death after Day
100*
Total
Deaths
No TBI (n 5 90) Sudden death,
unknown cause
(1)
GVHD related (2)
Hemolytic uremic
syndrome (1)
Veno-occlusive
disease (1)
GVHD-related (5)
(1 varicella
zoster virus)
Cardiac arrest (2)
Hemolytic anemia
(1)
Graft failure (1)
14
TBI (n 5 89) Pseudomonas
sepsis (1)
Cardiac failure (1)
Encephalopathy (1)
Parainfluenza (1)
Adult respiratory
distress
syndrome (1)
GVHD-related (4)
(1 pneumonia)
Infection (1)
Cardiac arrest (1)
Adult respiratory
distress
syndrome (1)
12
NRM indicates nonrelapse mortality; TBI, total body irradiation; GVHD,
graft-versus-host disease.
*Includes identified opportunistic infection when death was
GVHD-related.Subgroup Analysis
Outcomes of patients treated within 1 year of May
15, 2003, were analyzed. Differences in NRM between
patients not receiving or receiving TBI in NRM (37%
vs 16%) and relapse (51% vs 27%) did not reach statis-
tical significance. The corresponding differences for
DFS (30% vs 68%; P 5 .02) and OS (35% vs 68%;
P 5 .02) did differ significantly, however.DISCUSSION
Our initial experience suggested that adding ATG
to Flu/Bu combinations was well tolerated, but com-
pared with more conventional regimens was accompa-
nied by a trend toward more relapse, presumably by
diminishing the graft-versus-leukemia effect [5,6].
We chose to address this issue in AML by adding a rel-
atively small dose (400 cGy) of TBI. This resulted in
significant improvements in DFS and OS, because
relapse was reduced without an increase in NRM.
The effect was seen both in patients in CR and in those
with active disease.
Previous attempts to increase the intensity of con-
ventional MA regimens have not resulted in improved
survival, because any reduction in relapse achieved was
offset by higher NRM [1,2]. Conversely, relapse rates
Table 3. Pretransplantation Factors Affecting DFS and OS Based on Multivariate Cox Hazard Regression Analysis
Factor
DFS OS
HR 95% CI P HR 95% CI P
TBI 0.43 0.26-0.72 .001 0.50 0.30-0.84 .009
Age (per year increase) 1.03 1.01-1.05 .009 1.03 1.006-1.05 .004
Cytogenetic group 3 (vs
group 2)
2.7 1.42-4.29 .001 2.31 1.31-4.06 .004
High-risk disease 2.86 1.81-4.51 <.0001 2.49 1.54-4.03 .0002
Blood as stem cell source 0.51 0.26-0.99 .048 0.47 0.24-0.94 .032
DFS indicates disease-free survival; OS, overall survival; TBI, total body irradiation.
Biol Blood Marrow Transplant 16:509-514, 2010 513TBI with Flu/Bu/Thymoglobulin for AMLtended to increase as the intensity of conditioning was
reduced [3,11,12]. These findings, and those reported
here, provide evidence that regimen intensity is an im-
portant factor in the cure of AML by allogeneic
HSCT.
Some weaknesses of this study must be addressed.
The most important relate to the fact that most TBI
recipients were treated later on in the study and thus
may have benefited from improvements in supportive
care. The only change in the trial period that we can
identify is the introduction of new antifungal agents.
Fungal infection was not a cause of any NRM, how-
ever. Outcome analysis of patients treated within 1
year of the major change in practice to TBI demon-
strated significantly better OS and DFS in TBI recip-
ients. Although patients not given TBI over this period
fared particularly poorly, it seems unlikely that
changes in supportive care during the study period
are masking a tendency for TBI to increase NRM.
The fact that the TBI recipients included more
low-risk patients with secondary leukemia and/or
previous myelodysplastic syndrome (MDS) and fewer
previously untreated high-risk recipients may reflect
a move toward attempting to induce remission in pa-
tients with transforming MDS rather than proceeding
immediately to HSCT.Nonetheless, outcomes in TBI
recipients were unlikely to be improved in either sub-
group by these differences in risk factors compared
with patients not given TBI. Whereas the higher pro-
portion of blood cell recipients might be thought to
contribute to a lower relapse rate in patients given
TBI, we found no evidence of such an effect in this
study.
The addition of TBI appears to be a risk factor for
PTLD. Treatment was successful in our patients, but
clearly close monitoring for this complication is
important. Long-term toxicities of TBI include the
development of cataracts, endocrine abnormalities,
and growth arrest in children. Longer follow-up is
needed to determine whether the relatively low dose
of TBI in this regimen will result in a significantly
reduced incidence of these complications compared
with conventional doses.
The Flu/Bu/ATG regimen appears to be suffi-
ciently well tolerated to allow, allowing amodest esca-
lation in intensity without increasing NRM. Thisobservation begs the question of whether the drug reg-
imen is comparable in intensity to conventional com-
binations, such as cyclophosphamide (Cy) combined
with busulfan (Bu/Cy) or TBI doses of $1200 cGy
(Cy/TBI). We agree with de Lima et al. [4] that the
regimen should be considered reduced toxicity rather
than RIC. The i.v. Bu dose is equivalent to that used
in BuCy, and Cy is not a myeloablative agent, although
it may contribute to toxicity in combination with Bu or
TBI [13-15]. Andersson et al. [16] have provided evi-
dence that that the Flu/Bu regimen is better tolerated
than BuCy (with i.v. Bu) and has equivalent antileuke-
mic activity in AML. Our practice differs from that of
Andersson et al. by including ATG for matched sibling
HSCT as well as unrelated donor HSCT, perhaps re-
sulting in more relapse than in their studies in which
only the two drugs were used [4,16]. ATGmay reduce
the morbidity and mortality of both aGVHD and
cGVHD and improve the quality of life of surviving
patients [5,6,17]. We seem to have been able to reduce
relapse in our AML patients without sacrificing this
advantage.
Possibly a similar improvement in outcome could
be achieved without the need for TBI by targeting
Bu exposure to the high end of the therapeutic win-
dow. Studies exploring this issue are ongoing [16,18].
Our own (unpublished) experience so far indicates no
relationship between Bu exposure and relapse of
AML when TBI is added to the Flu/Bu regimen.
The finding that age, disease status, and cytoge-
netic abnormalities influence outcome in AML is not
unexpected. Only one patient underwent HSCT with
BM from a related donor. Thus, the superior overall
outcomes with blood as the hematopoietic stem cell
source reflects the influence of cell source from
alternate donors and is in contrast to the findings of
a recent analysis based on registry data [19]. This
conclusion may be valid only when the Flu/Bu/ATG
regimen is used. Ongoing randomized, controlled
studies should further clarify this issue.
In conclusion, this study confirms the importance
of regimen intensity in allogeneic HSCT for AML.
The combination of daily i.v. Bu, Flu, 400 cGy TBI,
and ATG provides a well-tolerated regimen with anti-
leukemic activity in AML comparable to that of other
conventional MA regimens.
514 Biol Blood Marrow Transplant 16:509-514, 2010J. A. Russell et al.ACKNOWLEDGMENTS
The authors thank the nursing staff at Foothills
Hospital, Tom Baker Cancer Centre, and Cross Can-
cer Institute for their care of the patients in this study.Authorship Statement
James Russell designed the study; Diana Quinlan
collected the data;William Irish and James Russell an-
alyzed the data; all authors cared for the patients;
James Russell prepared the manuscript; and all authors
interpreted data and critically revised the manuscript.
Financial disclosure: James Russell has received hon-
oraria from Genzyme and Otsuka Pharma and grant
support from Otsuka Pharma.REFERENCES
1. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow
transplantation in patients with acute myeloid leukemia in first
remission: a randomized trial of two irradiation regimens. Blood.
1990;76:1867-1871.
2. Alyea E, Neuberg D, Mauch P, et al. Effect of total body irradi-
ation dose escalation on outcome following T cell–depleted
allogeneic bone marrow transplantation. Biol Blood Marrow
Transplant. 2002;8:139-144.
3. Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hemato-
poietic stem cell transplantation in AML and MDS using
myeloablative versus reduced-intensity conditioning: the role
of dose intensity. Leukemia. 2006;20:322-328.
4. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous
busulfan and fludarabine: clinical and pharmacokinetic results of
a myeloablative, reduced-toxicity conditioning regimen for allo-
geneic stem cell transplantation in AML and MDS. Blood. 2004;
104:857-864.
5. Russell JA, Turner AR, Larratt L, et al. Adult recipients of
matched related donor blood cell transplants given myeloabla-
tive regimens including pretransplant antithymocyte globulin
have lower mortality related to graft-versus-host disease:
a matched pair analysis. Biol Blood Marrow Transplant. 2007;13:
299-306.
6. Bredeson CN, ZhangMJ, Agovi MA, et al. Outcomes following
HSCT using fludarabine, busulfan, and thymoglobulin:
a matched comparison to allogeneic transplants conditioned
with busulfan and cyclophosphamide. Biol Blood Marrow
Transplant. 2008;14:993-1003.
7. Russell JA, Savoie ML, Balogh A, et al. Allogeneic transplanta-
tion for adult acute leukemia in first and second remission
with a novel regimen incorporating daily intravenous busulfan,fludarabine, 400 cGY total body irradiation, and thymoglobulin.
Biol Blood Marrow Transplant. 2007;13:814-821.
8. Russell JA, Chaudhry A, Booth K, et al. Early outcomes after
allogeneic stem cell transplantation for leukemia and myelodys-
plasia without protective isolation: a 10-year experience. Biol
Blood Marrow Transplant. 2000;6:109-114.
9. Russell JA, Woodman RC, Poon MC, et al. Addition of low-
dose folinic acid to a methotrexate/cyclosporin A regimen for
prevention of acute graft-versus-host disease. Bone Marrow
Transplant. 1994;14:397-401.
10. Barrett J. Graft-versus-host disease. In: Treleaven J, Barrett J,
editors. Bone Marrow Transplantation in Practice. Edinburgh,
UK: Churchill Livingstone; 1992 p. 257.
11. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative
versus reduced-intensity conditioning regimens in the treatment
of acute myeloid leukemia and high-risk myelodysplastic
syndrome: dose is relevant for long-term disease control after
allogeneic hematopoietic stem cell transplantation. Blood.
2004;104:865-872.
12. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative
outcome of reduced-intensity and myeloablative conditioning
regimen in HLA-identical sibling allogeneic haematopoietic
stem cell transplantation for patients older than 50 years of
age with acute myeloblastic leukaemia: a retrospective survey
from the Acute Leukemia Working Party (ALWP) of the Euro-
pean group for Blood and Marrow Transplantation (EBMT).
Leukemia. 2005;19:2304-2312.
13. McCune JS, Batchelder A, Deeg HJ, et al. Cyclophospha-
mide following targeted oral busulfan as conditioning for he-
matopoietic cell transplantation: pharmacokinetics, liver
toxicity, and mortality. Biol Blood Marrow Transplant. 2007;
13:853-862.
14. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophospha-
mide metabolism, liver toxicity, and mortality following hema-
topoietic stem cell transplantation. Blood. 2003;101:2043-2048.
15. HassanM, Ljungman P, RingdenO, et al. The effect of busulfan
on the pharmacokinetics of cyclophosphamide and its 4-hydroxy
metabolite: time interval influence on therapeutic efficacy and
therapy-related toxicity. Bone Marrow Transplant. 2000;25:
915-924.
16. Andersson BS, de LimaM, Thall PF, et al. Once daily i.v. busul-
fan and fludarabine (i.v. Bu-Flu) compares favorably with i.v.
busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant
conditioning therapy in AML/MDS. Biol Blood Marrow
Transplant. 2008;14:672-684.
17. Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin
prevents chronic graft-versus-host disease, chronic lung
dysfunction, and late transplant-related mortality: long-term
follow-up of a randomized trial in patients undergoing unrelated
donor transplantation. Biol Blood Marrow Transplant. 2006;12:
560-565.
18. Russell JA, Kangarloo SB. Therapeutic drug monitoring of bu-
sulfan in transplantation. Curr Pharm Des. 2008;14:1936-1949.
19. Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts
from unrelated donors are associated with increased acute and
chronic graft-versus-host disease without improved survival.
Biol Blood Marrow Transplant. 2007;13:1461-1468.
